Table 1.
Baseline characteristics of patients who received dapagliflozin stratified by UACR response
| Baseline characteristics | Responders (n = 288) | Non‐responders (n = 243) |
|---|---|---|
| Age, y | 59.3 (10.3) | 60.0 (8.8) |
| Women | 121 (42.0) | 68 (28.0) |
| Men | 167 (58.0) | 175 (72.0) |
| Race | ||
| White | 244 (84.7) | 202 (83.1) |
| Black | 12 (4.2) | 9 (3.7) |
| Asian | 28 (9.7) | 22 (9.1) |
| Other | 4 (1.4) | 10 (4.1) |
| Duration of type 2 diabetes, y | 10.6 (8.9) | 10.6 (8.2) |
| UACR, mg/g | 86.0 (48.5–165.5) | 69.0 (42.0–162.0) |
| ≥30 to <300 | 240 | 197 |
| ≥300 | 44 | 46 |
| Body weight, kg | 91.5 (19.6) | 93.9 (22.7) |
| sUA, mg/dL | 5.60 (1.5) | 5.88 (1.7) |
| HbA1c, % | 8.38 (0.9) | 8.15 (0.9) |
| HbA1c, mmol/mol | 68 | 66 |
| Haematocrit, % | 42.1 (4.2) | 42.6 (4.0) |
| Serum bicarbonate, mEq/L | 25.3 (2.8) | 25.8 (3.0) |
| SBP, mm Hg | 136.8 (15.3) | 136.6 (14.8) |
| DBP, mm Hg | 79.6 (9.9) | 78.7 (8.8) |
| Pulse pressure, mm Hg | 57.2 (13.8) | 57.9 (13.1) |
| eGFR, mL/min/1.73 m2 | 80.3 (19.2) | 80.7 (21.1) |
| ≥30 to <45 | 7 (2.4) | 7 (2.9) |
| ≥45 to <60 | 26 (9.0) | 36 (14.8) |
| ≥60 to <90 | 176 (61.1) | 118 (48.6) |
| ≥90 | 79 (27.4) | 82 (33.7) |
| Baseline medications | ||
| Loop diuretics | 35 (12.2) | 42 (17.3) |
| Thiazide diuretics | 31 (10.8) | 18 (7.4) |
| ACEi/ARB | 226 (78.5) | 190 (78.2) |
| Insulin | 125 (43.4) | 103 (42.4) |
| SU | 82 (28.5) | 81 (33.3) |
| TZD | 72 (25.0) | 55 (22.6) |
| DPP4 inhibitors | 27 (9.4) | 18 (7.4) |
| Disease history | ||
| CVD and/or HF | 160 (55.6) | 158 (65.0) |
| Hypertension | 237 (82.3) | 208 (85.6) |
| Dyslipidaemia | 195 (67.7) | 190 (78.2) |
| PVD/PAD | 42 (14.6) | 47 (19.3) |
Abbreviations: ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CVD, cardiovascular disease; DBP, diastolic blood pressure; DPP4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; HF, heart failure; PAD, peripheral arterial disease; PVD, peripheral vascular disease; SBP, systolic blood pressure; SD, standard deviation; SU, sulphonylurea; sUA, serum uric acid; T2D, type 2 diabetes; UACR, urine albumin : creatinine ratio. Data are presented as mean (SD) or number (%). UACR values represent median (25th, 75th percentile) values in patients with UACR ≥30 mg/g at baseline.